Search | Clinical Trials Finder

Conditions: Coronary Artery Disease, Sternal Pain
Interventions: Bupivacaine Group, Placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Sickle Cell Anemia
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions: Pegloticase 8 MG/ML [Krystexxa]; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Advanced Cancer, Dehydration
Interventions: Saline; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: ZTI-01, Moxifloxacin 400mg, Placebo IV; Drug · Other
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Labor Pain
Interventions: Terbutaline, Fentanyl, 0.9% NaCl; Drug
Lead sponsor: Kai Schoenhage; Other
Eligibility: 18 Years to 53 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Pregnancy
Interventions: Lidocaine, Normal Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury
Interventions: 0.9% sodium chloride, Physiologically balanced fluid; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Herpes Zoster
Interventions: Live attenuated herpes zoster vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee

Conditions: Alzheimer Disease
Interventions: TB006, Sterile saline (Placebo); Drug · Other
Lead sponsor: TrueBinding, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Breast Cancer
Interventions: Eribulin, Carboplatin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid, Sedation and Analgesia
Interventions: Acetaminophen, Ketorolac, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Months to 17 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Ann Arbor, Michigan + 13 more

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
Interventions: Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication
Interventions: Norepinephrine, Lactated Ringers, Intravenous, normal saline, Plasma-lyte; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Rheumatoid Arthritis
Interventions: VIB4920, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 18
States / cities: Anniston, Alabama • Sun City, Arizona • Upland, California + 15 more

Conditions: Lower Urinary Tract Symptoms
Interventions: Lactobacillus; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 6 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Thyroidectomy, Nerve Monitoring
Interventions: Lidocaine, Placebo; Drug
Lead sponsor: Bronx-Lebanon Hospital Center Health Care System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Smoking, Smoking Cessation
Interventions: Oxytocin, Mindfulness, Saline Solution, Sham mindfulness; Drug · Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Dyslipidemias
Interventions: Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Uric Acid Lowering Trial in Youth Onset T2D

Parenteral Hydration in Advanced Cancer Patients

4-way Crossover QT Evaluation in Healthy Subjects

Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement

Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery

Isotonic Solution Administration Logistical Testing

ZOSTAVAX® in Renal Transplant Patients

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Optimizing Pain Treatment in Children On Mechanical Ventilation

Treatment of Orthostatic Intolerance

Trigger Point Injections in Anterior Cervical Surgery

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)